Pharma Focus Asia

SeqirusConstructs World Class Vaccine Manufacturing Facility in Australia

Introduction:
Seqirus, a global leader in influenza prevention and influenza pandemic responseplans to construct a new next-generation vaccine manufacturing facility. The new manufacturing facility will be located in Australia.

Features:
The state-of-the-art facilitywill be constructed with an investment of US$800 million. This facility makes use of innovative cell-based technology for the production of influenza vaccinesfor both influenza pandemics and seasonal vaccination programs.

The manufacturing facility is being constructed to provide influenza vaccinesto Australia and rest of the world. The facility is supposed to be the only cell-based influenzavaccine productionfacility in the Southern Hemisphere. Moreover, it also produces a material known as Seqirus’ proprietary adjuvant MF59®. MF59®added to the vaccines will improve immune responsebydecreases the amount of antigen required for each vaccine and thus enabling for the production of doses more rapidly.

Cell-based influenza vaccine technology offers many advantages over the current process togetherwith more scalability and offering faster production.

The new state-of-the-art manufacturing facility is expected to be completed and be operational by mid-2026.

Specifications:

NameSeqirus
TypeNew Construction
BudgetUS$800 million
Year2026

 

magazine-slider-imageHexagon - Expert Insights WebinarMFA + MMA 20244th Annual Cleaning Validation 20242nd Annual Pharma Impurity Conclave 2024CPHI Korea 2024CHEMICAL INDONESIA 2024World Orphan Drug Congress Europe 2024INALAB 2024Thermo Fisher - Drug Discovery and the impact of mAbsAdvanced Therapies USA 2024ISPE Singapore Affiliate Conference & Exhibition 20242024 PDA Aseptic Manufacturing Excellence Conference2024 PDA Aseptic Processing of Biopharmaceuticals Conference